- Home
- CUE vs GRF Comparison
CUE vs GRF Comparison
Compare CUE & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | GRF |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 42.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | GRF |
|---|---|---|
| Price | $0.49 | $11.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 249.2K | 3.0K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $7,100,000.00 | N/A |
| Revenue This Year | $36.58 | N/A |
| Revenue Next Year | $32.10 | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $7.93 |
| 52 Week High | $1.75 | $10.19 |
Technical Indicators
Market Signals| Indicator | CUE | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 67.87 |
| Support Level | $0.47 | $9.70 |
| Resistance Level | $0.51 | $10.08 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 10.78 | 97.30 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.